Menin-Inhibitor Targeted Maintenance in AML

Menin is a critical cofactor for oncogenic transcriptional programs in AML subsets driven by KMT2A rearrangements, NPM1 mutations, and NUP98 rearrangements. The interaction between menin and KMT2A promotes aberrant expression of HOX and MEIS genes, maintaining leukemic self-renewal and blocking differentiation. Revumenib is a potent, selective, oral small-molecule inhibitor of the menin-KMT2A interaction that has demonstrated clinical activity in relapsed or refractory AML. Beyond its direct anti-leukemic effects, emerging preclinical data indicate that menin inhibition may favorably modulate leukemia-immune interactions in the post-transplant environment. Menin inhibition has been shown to induce myeloid differentiation and increase expression of antigen presentation machinery, including MHC class II, in KMT2Ar and NPM1m AML. This effect is mediated through activation of interferon-related signaling pathways and results in enhanced recognition of leukemia cells by donor T cells. In parallel, menin inhibition has been shown to augment donor T-cell effector function and reduce T-cell exhaustion, collectively strengthening the GVL response without directly increasing alloreactivity against normal tissues.

Findings suggest that revumenib may function as a dual-mechanism maintenance therapy following allo-HCT which includes 1) suppressing residual leukemic clones by disrupting menin-dependent transcriptional programs, and 2) enhancing immune-mediated leukemia control by improving leukemia immunogenicity and donor T-cell function. Importantly, revumenib is orally administered and has a manageable and well-characterized safety profile, making it suitable for prolonged administration in the post-transplant setting with appropriate monitoring.